Compare Ginkgo Bioworks Holdings Inc (DNA) vs ON Holding AG (ONON) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.

DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.

ONON stock is trading at $31.01, down 20.04% after Q2 2026 results showed a revenue miss and lowered full-year growth guidance. The technical picture is bearish with support near $29, while fundamentals reveal strong profitability margins and earnings beats. Analyst sentiment remains largely positive despite the sell-off, with a consensus price target of $52.86.

The outlook is mixed: robust DTC growth and margin expansion offer upside, but wholesale softness and guidance cuts pose near-term risks. Investors face volatility from consumer spending concerns and competitive pressures, though long-term brand momentum supports a growth-at-a-reasonable-price thesis.